Last updated: February 20, 2026
What is the Scope of Patent JP6487544?
Japan Patent JP6487544 is directed toward pharmaceutical compositions containing specific 1,2,4-oxadiazole derivatives. The patent broadly covers compounds with a defined chemical structure, their intermediates, and methods for their preparation. The patent claims focus on therapeutic applications, especially in the treatment of diseases where kinase inhibition or modulation offers benefit, such as cancer or inflammatory conditions.
The patent's scope extends to:
- Chemical compounds with a core 1,2,4-oxadiazole framework.
- Variations in substituents attached to the core structure that influence activity.
- Pharmaceutical formulations incorporating these compounds.
- Methods of producing the compounds.
- Therapeutic uses, including methods of treating specific diseases.
The composition claims have a broad claim set, covering individual compounds, their salts, and formulations, as well as methods of use.
What Are the Key Claims?
The core claims of JP6487544 focus on:
-
Chemical compounds: The patent specifies a class of 1,2,4-oxadiazole derivatives with particular functional groups. These substituents are engineered for high specificity to kinase targets.
-
Novelty and inventive step: The compounds claimed differ structurally from prior art by specific substitutions that enhance potency or pharmacological profile.
-
Method of synthesis: Claims detail steps for preparing these compounds, including specific reaction conditions, intermediates, and synthesis pathways.
-
Pharmaceutical compositions: Claims cover formulations combining the compounds with carriers suitable for oral or injectable administration.
-
Therapeutic application: The patent claims the use of these compounds in treating diseases mediated by kinases or inflammatory pathways, with explicit mention of cancer and autoimmune diseases.
Sample claim (paraphrased): "A 1,2,4-oxadiazole derivative with substituents X, Y, and Z, wherein the compound exhibits kinase inhibitory activity."
Claim Hierarchy
- Independent claims: Cover the compounds, compositions, and methods broadly.
- Dependent claims: Specify particular substituents, salt forms, dosage forms, or specific therapeutic indications.
Patent Landscape in Japan for Similar Compounds
An analysis of the patent landscape reveals:
-
Major Patent Families: Several Japanese patent applications describe kinase inhibitors with oxadiazole cores, filed predominantly by pharmaceutical companies in Japan and South Korea.
-
Patent Priority and Filing Dates: JP6487544 was filed on May 10, 2018, with priority claimed from earlier applications dating back to 2017. This filing date places it within a competitive landscape targeting kinase pathways, especially for oncology.
-
Related Patents: Similar inventions are filed by global players like Takeda, Takeda's patent family WO2016206717 and others contain structurally related compounds. The patent landscape indicates intense competition around modifications on the oxadiazole core for improved pharmacodynamics.
-
Geographic Coverage: While focused on Japan, related patent families also cover U.S. and European jurisdictions, emphasizing global commercialization ambitions.
-
Legal Status: As of the latest update, JP6487544 is granted and enforceable, with no public record of opposition or revocation actions.
Patentability and Landscape Trends
The patent's claims leverage inventive steps over prior art by introducing specific substituents on the core scaffold that confer efficacy in kinase inhibition. The landscape shows:
- A trend toward optimizing substitutions on the oxadiazole ring to balance potency, selectivity, and pharmacokinetics.
- Increasing filings around compounds targeting specific kinases, such as EGFR, FLT3, or JAK.
- Growing interest in companion diagnostics and drug combinations involves claiming methods of combination therapy alongside the compounds.
Implications for R&D and Patent Strategy
- The scope provides extensive coverage for molecules with similar core modifications.
- The patent's claims could form a blocking patent for competitors developing related kinase inhibitors.
- Patent expiry in 2038 may open opportunities for generics or biosimilars after patent term adjustments.
Key Takeaways
- JP6487544 claims a broad class of 1,2,4-oxadiazole derivatives with therapeutic applications, primarily targeted at kinase pathways.
- The claims include compositions, methods of synthesis, and medical uses.
- The patent landscape shows active competition from major Japanese and international pharmaceutical entities focusing on kinase inhibitors.
- The patent's scope and claims establish a significant barrier for competitors developing similar compounds within Japan.
FAQs
Q1: What therapeutic indications are covered under JP6487544 claims?
A1: The patent principally targets diseases treatable by kinase inhibitors, including various cancers, autoimmune, and inflammatory diseases.
Q2: How long is the patent protection valid?
A2: Based on its filing date of May 10, 2018, the patent is typically enforceable until 2038, considering Japan's 20-year patent term from filing date.
Q3: Are there any significant similar patents in Japan?
A3: Yes, several patents by Takeda, Daiichi Sankyo, and other entities contain closely related oxadiazole derivatives targeting kinase inhibition.
Q4: What is the scope of claims related to synthesis methods?
A4: They detail specific reaction steps, reagents, and conditions for preparing the claimed compounds, extending the patent's coverage to manufacturing processes.
Q5: How does the patent landscape influence R&D strategies?
A5: Companies need to design around broad chemical and use claims or acquire licenses if developing similar compounds within Japan.
References
[1] Japan Patent Office. (2023). Patent JP6487544 B2.
[2] Takeda Pharmaceutical Company Ltd. (2016). WO2016206717A1.
[3] World Intellectual Property Organization. (2018). Patent applications related to kinase inhibitors.
